Summary Chronic kidney disease (CKD) due to glomerulonephritis was responsible for 6·90 million (95% UI 5·78–8·13) DALYs and 16·6% (14·3–19·2) of total overall CKD DALYs in 2019.

Definition This causes incorporates death and disability due to chronic kidney disease that is due to glomerulonephritis.

Total sources
Incidence 0
Prevalence 0
Remission 0
Causes of death 0
Other 353
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •Excess mortality data (EMR) were modelled in MR-BRT by age and sex as a function of HAQ Index.
  • •Adjustments for alternative CKD estimating equations were applied prior to DisMod-MR. These adjustments increased estimates for stage 3 but resulted in small changes for stages 4 and 5 compared to previous rounds of GBD. The reference equation is CKD-EPI.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
17·3
(16·1
to 18·6)
217·1
(201·3
to 233·5)
0·606
(0·560
to 0·658)
7·9
(7·3
to 8·5)
0·184
(0·146
to 0·229)
2·3
(1·9
to 2·9)
5·55
(4·54
to 6·70)
69·4
(56·9
to 83·2)
1·35
(0·911
to 1·81)
16·8
(11·4
to 22·4)
6·90
(5·78
to 8·13)
86·2
(72·3
to 101·2)
Females
7·09
(6·56
to 7·68)
177·1
(163·9
to 191·2)
0·196
(0·181
to 0·213)
5·2
(4·8
to 5·6)
0·0806
(0·0634
to 0·102)
1·9
(1·5
to 2·4)
2·35
(1·87
to 2·90)
57·6
(45·9
to 70·8)
0·650
(0·442
to 0·869)
16·2
(11·0
to 21·6)
3·00
(2·49
to 3·56)
73·7
(61·3
to 87·0)
Males
10·2
(9·46
to 11·0)
257·3
(238·2
to 276·3)
0·410
(0·378
to 0·444)
10·6
(9·8
to 11·5)
0·103
(0·0826
to 0·128)
2·8
(2·3
to 3·6)
3·20
(2·62
to 3·87)
82·2
(68·1
to 98·7)
0·696
(0·469
to 0·939)
17·4
(11·8
to 23·4)
3·90
(3·26
to 4·59)
99·6
(84·1
to 116·8)
Percentage change 2010-19
Both Sexes
17·0%
(16·0
to 17·9)
3·8%
(3·0
to 4·7)
19·2%
(18·0
to 20·5)
7·0%
(6·0
to 8·0)
26·4%
(18·3
to 33·9)
1·5%
(–4·3
to 6·9)
16·7%
(9·0
to 24·3)
–0·4%
(–6·4
to 5·4)
14·8%
(12·3
to 17·5)
1·3%
(–0·7
to 3·4)
16·3%
(10·4
to 22·5)
–0·1%
(–4·9
to 4·7)
Females
15·4%
(14·2
to 16·4)
2·1%
(1·2
to 3·0)
16·4%
(15·1
to 18·0)
4·7%
(3·5
to 6·0)
27·4%
(17·5
to 37·9)
2·0%
(–5·7
to 9·8)
16·8%
(6·5
to 27·6)
–0·6%
(–8·8
to 8·1)
14·1%
(11·1
to 17·1)
1·0%
(–1·3
to 3·4)
16·2%
(8·2
to 24·8)
–0·3%
(–6·7
to 6·8)
Males
18·2%
(17·1
to 19·2)
4·9%
(4·0
to 5·9)
20·6%
(19·4
to 21·9)
8·1%
(7·1
to 9·0)
25·6%
(16·7
to 34·1)
0·6%
(–5·8
to 6·8)
16·6%
(8·2
to 25·2)
–0·4%
(–7·1
to 6·5)
15·5%
(12·7
to 18·5)
1·5%
(–0·9
to 3·9)
16·4%
(9·4
to 23·4)
–0·1%
(–5·7
to 5·5)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 85th 84th 113th 104th
2010 65th 72nd 103rd 89th
2019 59th 62nd 102nd 84th
Table 3: Rank among most detailed causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by YLLs and constituent sequelae YLDs for both sexes combined, 2019
Figure 2: Percentage of DALYs attributable to top risk factors for both sexes combined, 2019
No Legend
Figure 3: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 4: Composition of DALYs by YLLs and YLDs, age group, and sex, 2019
No Legend
Figure 5: Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019